The partnership and technologies developed by Cure First, SEngine Precision Medicine, in collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine, led to a seminal study in prostate cancer. Personalized cancer models from patients were developed and novel therapeutic combinations discovered and validated.
See the Fred Hutch Science Spotlight about the published Clinical Cancer Research paper.
Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine
Academic Industrial Partnership for Translation of Technologies for Cancer Diagnosis and Treatment
Scientists from Cure First and SEngine Precision Medicine discover common link in 28% of all cancers
Cure First, a non-profit research organization, and SEngine Precision Medicine co-authored one of 27 high-profile papers published today by Cell Press.
SEngine partners with Knight Cancer Institute at OHSU and Fred Hutch researchers to bring personalized, cancer-fighting tech to patients.
SEngine team presenting five posters at American Association for Cancer Research annual conference.
Got f(x)? Join The Society for Functional Precision Medicine (SFPM) and help advance the science and medicine of direct functional testing of patient cancer cells. SFPM's mission is to facilitate implementation of functional assays into clinical care.
CELL Press released 27 papers which are part of the PanCancer Atlas. SEngine in-depth analysis of the MYC oncogene across 11,000 samples and 33 tumor types published in Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Incredible speakers tackle key challenges. The Seattle conference tackles the future of functional precision oncology.
Breakthrough approach to functional precision oncology and rapid cancer drug discovery is covered by Seattle Business Magazine Editor in Chief Leslie Helm.
The Young Lions – Harnessing Next Generation Technologies to Help Current Cancer Patients and the Oncologists Who Treat Them
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations. Click here to read the paper in Cancer Discovery (PMID_28331002).
SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center
Nature Medicine cites SEngine collaborative work with Cornell Institute for Precision Medicine. July 2017 23(7) 796-799, (PMID_28697178)
A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery May 2017 PMID_28461408
SEngine CLIA certification makes the P.A.R.I.S. cancer test available to patients. The P.A.R.I.S. Assay employs live cancer cells to evaluate the response to >120 drugs on a given patient cancer sample in a matter of few weeks.
There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.